Last reviewed · How we verify
Symlin (pramlintide)
Pramlintide is an amylin analog that slows gastric emptying, reduces postprandial glucagon secretion, and increases satiety to improve blood glucose control in diabetes.
Pramlintide is an amylin analog that slows gastric emptying, reduces postprandial glucagon secretion, and increases satiety to improve blood glucose control in diabetes. Used for Type 1 diabetes mellitus (adjunct to insulin therapy), Type 2 diabetes mellitus (adjunct to insulin therapy).
At a glance
| Generic name | Symlin (pramlintide) |
|---|---|
| Sponsor | Baylor College of Medicine |
| Drug class | Amylin analog |
| Target | Amylin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pramlintide mimics amylin, a hormone co-secreted with insulin that regulates postprandial glucose excursions. It acts on amylin receptors to delay gastric emptying, suppress glucagon secretion during the postprandial period, and promote satiety. These combined effects reduce postmeal blood glucose spikes in patients with type 1 and type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus (adjunct to insulin therapy)
- Type 2 diabetes mellitus (adjunct to insulin therapy)
Common side effects
- Nausea
- Vomiting
- Anorexia
- Hypoglycemia
- Headache
Key clinical trials
- Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide (NA)
- Amylin-Induced Migraine Attacks Without Aura (NA)
- Hypersensitivity to Amylin in Post-Traumatic Headache (NA)
- Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (EARLY_PHASE1)
- Tailoring Obesity Treatment Trial (PHASE2, PHASE3)
- A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes (PHASE2, PHASE3)
- Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D (PHASE2)
- The Role of Amylin in Bone Metabolism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symlin (pramlintide) CI brief — competitive landscape report
- Symlin (pramlintide) updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI